Abattis Bioceuticals Corp. (OTCPK:ATTB.F) agreed to acquire Pro Natura BV from The Catalyst Capital Group Inc. for €15.7 million on March 27, 2019. The consideration includes €2 million paid on closing, €2.2 million one year following closing, €2.5 million one year following closing and buyer also agreed to pay €5 million within two years of Abattis CBD products being launched through Pro Natura's sales and €4 million within two years of launch of sales of Abattis's proprietary product, Comfort, through Pro Natura's sales channels. The transaction is subject to approval from Board of Catalyst Capital and Abattis Bioceuticals, approval from Canadian Stock Exchange, resignation of Directors and officers of Pro Natura and other precedent closing conditions. The transaction is expected to close by mid-April 2019.